Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $88.01 USD
Change Today -1.36 / -1.52%
Volume 716.9K
DXCM On Other Exchanges
Symbol
Exchange
DXCM is not on other exchanges.
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

dexcom inc (DXCM) Snapshot

Open
$89.89
Previous Close
$89.37
Day High
$90.64
Day Low
$87.82
52 Week High
08/14/15 - $98.85
52 Week Low
10/2/14 - $38.77
Market Cap
7.0B
Average Volume 10 Days
1.3M
EPS TTM
$-0.31
Shares Outstanding
80.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DEXCOM INC (DXCM)

dexcom inc (DXCM) Related Businessweek News

No Related Businessweek News Found

dexcom inc (DXCM) Details

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes DexCom G4 system, a continuous glucose monitoring system; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring. Its in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. The company also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. DexCom, Inc. markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. The company was founded in 1999 and is headquartered in San Diego, California.

838 Employees
Last Reported Date: 02/25/15
Founded in 1999

dexcom inc (DXCM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $325.0K
Executive Chairman
Total Annual Compensation: $420.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $248.9K
Chief Technical Officer and Executive Vice Pr...
Total Annual Compensation: $296.4K
Executive Vice President of Strategy & Corpor...
Total Annual Compensation: $296.4K
Compensation as of Fiscal Year 2014.

dexcom inc (DXCM) Key Developments

DexCom, Inc. Announces FDA Approve Dexcom G5 Mobile Continuous Glucose Monitoring System

Dexcom, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System. With wireless Bluetooth® technology built into the device transmitter, the G5 Mobile CGM System is the first and only fully mobile CGM system approved by the FDA for both adults and children as young as 2 years of age that sends glucose data directly to a smartphone, freeing users from the need to carry a separate receiver. The new transmitter securely sends vital glucose information directly to an app on iOS-enabled devices for real-time diabetes management. Android applications will follow early next year. Like its predecessor, the G4 PLATINUM CGM with Share, users can also select up to five designated recipients, or "followers." These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere. Available by prescription, the Dexcom G5 Mobile CGM System features the most accurate glucose sensor on the market while providing enhanced mobility and flexibility to view and share personal glucose data and trends. The only CGM with single digit MARD (Mean Absolute Relative Difference), the Dexcom G5 Mobile comes with the longest-wear sensor on the market and features customizable alerts and a built-in low glucose alarm (55 mg/dL alarm) to warn patients of highs and lows and how quickly they may be happening through a simplified mobile interface. Data from the Dexcom G5 Mobile can be integrated with Dexcom CLARITYTM, a Cloud-based reporting software, for personalized, easy-to-understand analysis of trends that may improve diabetes management.

DexCom, Inc. - Special Call

To discuss that the company entered into an agreement with the life sciences team at Google to jointly develop a series of next-generation CGM products

DexCom, Inc. Enters Agreement with Google to Jointly Develop Series of Next-Generation CGM Products

DexCom, Inc. announced that it has entered into an agreement with the life sciences team at Google to jointly develop a series of next-generation CGM products that are designed to be smaller and less expensive than existing technologies. These new products will incorporate Google’s miniaturized electronics platform with DexCom’s best-in-class sensor technology. This collaboration also provides an opportunity to better utilize the data generated by these CGM products to significantly improve the outcomes and reduce the costs associated with diabetes care. Initial products to be developed under the agreement will focus on minimizing both the cost and size of CGM body worn components. The products will be designed to be disposable, and will be intended for use across all diabetes markets. The goal is to empower more people to control their diabetes with real-time and actionable information by developing a low-cost, small, bandage-sized sensor that is connected to the cloud.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DXCM:US $88.01 USD -1.36

DXCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.14 USD -0.10
Insulet Corp $28.24 USD -0.51
Merge Healthcare Inc $7.09 USD 0.00
Smiths Group PLC 1,094 GBp -20.00
Tandem Diabetes Care Inc $11.61 USD -0.24
View Industry Companies
 

Industry Analysis

DXCM

Industry Average

Valuation DXCM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.3x
Price/Book 41.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEXCOM INC, please visit www.dexcom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.